What should I avoid while taking Ziprasidone 80mg capsules?

Avoid alcohol. Take with food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Ziprasidone 80mg capsules?

Ziprasidone 80mg capsules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Ziprasidone 80mg capsules?

Ziprasidone 80mg capsules is the generic name. It is available under brand names including: Zeldox 80mg capsules. (Source: NHS dm+d — Actual Medicinal Products)

Ziprasidone 80mg capsules

Prescription only

Requires a prescription from a doctor or prescriber

Capsule

80mg

Oral

Drugs used in psychoses and related disorders

Active ingredients:

Ziprasidone

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.02.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N05AE04

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Ziprasidone

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Ziprasidone

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Ziprasidone

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Ziprasidone

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Ziprasidone on the MHRA register

Zeldox 80mg capsules

Imported (Sweden)

None

Imported

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

80 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Ziprasidone 20mg capsules

Capsule

20mg

Same therapeutic group

Lurasidone 18.5mg tablets

Tablet

18.5mg

Same therapeutic group

Lurasidone 37mg tablets

Tablet

37mg

Same therapeutic group

Lurasidone 74mg tablets

Tablet

74mg

Same therapeutic group

Ziprasidone 60mg capsules

Capsule

60mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Ziprasidone

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Rehabilitation for adults with complex psychosis (NG181)

NG181

NICE guideline

Updated Aug 2020

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Ziprasidone

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

19525911000001107

dm+d ID

19525911000001107

VTM (Virtual Therapeutic Moiety)

777985009

VMP (Virtual Medicinal Product)

19525911000001107

BNF code

04020100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N05AE04

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

18 found

Half-life

6-7 hours

Mechanism

The effects of ziprasidone are differentiated from other antispychotics based on…

Food interactions

2 warnings

Human targets

27 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

60%

In the absence of food, ziprasidone's oral bioavailability is 60%, and absorption may reach 100% if ziprasidone is taken with a meal containing at least 500 kcal.…

Half-life

6-7 hours

The half life of ziprasidone is 6-7 hours.
[A174562]

Protein binding

99%

Ziprasidone is extensively protein bound with over 99% of the drug bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
[A190594][L7342]…

Volume of distribution

1.5 L/kg

The mean apparent volume of distribution of Ziprasidone is 1.5 L/kg.
[L7342]

Metabolism

Ziprasidone is heavily metabolized in the liver with less than 5% of the drug excreted unchanged in the urine.
[A174277]…

Elimination

Ziprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug.

Clearance

7.5 mL/min/kg

The mean apparent systemic clearance is 7.5 mL/min/kg.
[L7342]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525]

Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525][A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534][A190537]

Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]

Properties:

solid

Avg. mass: 412.94 Da

DrugBank indication

In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder.
[L7342]
The injectable formulation is approved only for treatment of acute agitation in schizophrenia.
[L7342]

Also known as(141)

Ziprasidona

Ziprasidone

Ziprasidonum

Dopamine D2 receptor

5-HT-2

5-HT-2A

HTR2

Serotonin receptor 2A

Dosage forms(18)

Capsule (Oral) — 20 mg/1

Capsule (Oral) — 40 mg/1

Capsule (Oral) — 60 mg/1

Capsule (Oral) — 80 mg/1

Injection, powder, lyophilized, for solution (Intramuscular) — 20 mg/1mL

Suspension (Oral) — 1.000 g

Capsule, coated (Oral) — 20 mg

Capsule, coated (Oral) — 8000000 mg

Molecular properties(19)

Drug interactions(2165)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Hydrocodone

Moderate

DB00956

Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Ziprasidone can be increased when used in combination with Magnesium sulfate.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.

Check this interaction

Suvorexant

Moderate

DB09034

Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.

Check this interaction

Thalidomide

Moderate

DB01041

Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Brexpiprazole

Moderate

DB09128

The metabolism of Brexpiprazole can be decreased when combined with Ziprasidone.

Check this interaction

Eliglustat

Moderate

DB09039

The metabolism of Eliglustat can be decreased when combined with Ziprasidone.

Check this interaction

Everolimus

Moderate

DB01590

The metabolism of Everolimus can be decreased when combined with Ziprasidone.

Check this interaction

Flibanserin

Moderate

DB04908

The metabolism of Flibanserin can be decreased when combined with Ziprasidone.

Check this interaction

Ibrutinib

Moderate

DB09053

The metabolism of Ibrutinib can be decreased when combined with Ziprasidone.

Check this interaction

Ivabradine

Moderate

DB09083

The metabolism of Ivabradine can be decreased when combined with Ziprasidone.

Check this interaction

Ivacaftor

Moderate

DB08820

The metabolism of Ivacaftor can be decreased when combined with Ziprasidone.

Check this interaction

Naloxegol

Moderate

DB09049

The metabolism of Naloxegol can be decreased when combined with Ziprasidone.

Check this interaction

Olaparib

Moderate

DB09074

The metabolism of Olaparib can be decreased when combined with Ziprasidone.

Check this interaction

Sonidegib

Moderate

DB09143

The metabolism of Sonidegib can be decreased when combined with Ziprasidone.

Check this interaction

Avanafil

Moderate

DB06237

The metabolism of Avanafil can be decreased when combined with Ziprasidone.

Check this interaction

Eplerenone

Moderate

DB00700

The metabolism of Eplerenone can be decreased when combined with Ziprasidone.

Check this interaction

Aclidinium

Unknown severity

DB08897

The risk or severity of adverse effects can be increased when Ziprasidone is combined with Aclidinium.

Check this interaction

Potassium chloride

Unknown severity

DB00761

The risk or severity of gastrointestinal ulceration can be increased when Ziprasidone is combined with Potassium chloride.

Check this interaction

Pramlintide

Unknown severity

DB01278

The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Ziprasidone.

Check this interaction

Secretin porcine

Moderate

DB09527

The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Ziprasidone.

Check this interaction

Tiotropium

Unknown severity

DB01409

The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiotropium.

Check this interaction

Topiramate

Unknown severity

DB00273

The risk or severity of hyperthermia and oligohydrosis can be increased when Ziprasidone is combined with Topiramate.

Check this interaction

Umeclidinium

Unknown severity

DB09076

The risk or severity of adverse effects can be increased when Ziprasidone is combined with Umeclidinium.

Check this interaction

Desmopressin

Unknown severity

DB00035

The risk or severity of hypertension can be increased when Desmopressin is combined with Ziprasidone.

Check this interaction

Icosapent

Unknown severity

DB00159

The risk or severity of hypertension can be increased when Icosapent is combined with Ziprasidone.

Check this interaction

Mesalazine

Unknown severity

DB00244

The risk or severity of hypertension can be increased when Mesalazine is combined with Ziprasidone.

Check this interaction

Indomethacin

Unknown severity

DB00328

The risk or severity of hypertension can be increased when Ziprasidone is combined with Indomethacin.

Check this interaction

Ketorolac

Unknown severity

DB00465

The risk or severity of hypertension can be increased when Ziprasidone is combined with Ketorolac.

Check this interaction

Tenoxicam

Unknown severity

DB00469

The risk or severity of hypertension can be increased when Ziprasidone is combined with Tenoxicam.

Check this interaction

Tolmetin

Unknown severity

DB00500

The risk or severity of hypertension can be increased when Ziprasidone is combined with Tolmetin.

Check this interaction

Piroxicam

Unknown severity

DB00554

The risk or severity of hypertension can be increased when Ziprasidone is combined with Piroxicam.

Check this interaction

Doxapram

Unknown severity

DB00561

The risk or severity of hypertension can be increased when Ziprasidone is combined with Doxapram.

Check this interaction

Fenoprofen

Unknown severity

DB00573

The risk or severity of hypertension can be increased when Ziprasidone is combined with Fenoprofen.

Check this interaction

Sulindac

Unknown severity

DB00605

The risk or severity of hypertension can be increased when Ziprasidone is combined with Sulindac.

Check this interaction

Flurbiprofen

Unknown severity

DB00712

The risk or severity of hypertension can be increased when Ziprasidone is combined with Flurbiprofen.

Check this interaction

Etodolac

Unknown severity

DB00749

The risk or severity of hypertension can be increased when Ziprasidone is combined with Etodolac.

Check this interaction

Mefenamic acid

Unknown severity

DB00784

The risk or severity of hypertension can be increased when Ziprasidone is combined with Mefenamic acid.

Check this interaction

Sulfasalazine

Unknown severity

DB00795

The risk or severity of hypertension can be increased when Ziprasidone is combined with Sulfasalazine.

Check this interaction

Carprofen

Unknown severity

DB00821

The risk or severity of hypertension can be increased when Ziprasidone is combined with Carprofen.

Check this interaction

Phenmetrazine

Unknown severity

DB00830

The risk or severity of hypertension can be increased when Ziprasidone is combined with Phenmetrazine.

Check this interaction

Diflunisal

Unknown severity

DB00861

The risk or severity of hypertension can be increased when Ziprasidone is combined with Diflunisal.

Check this interaction

Salicylic acid

Unknown severity

DB00936

The risk or severity of hypertension can be increased when Ziprasidone is combined with Salicylic acid.

Check this interaction

Meclofenamic acid

Unknown severity

DB00939

The risk or severity of hypertension can be increased when Ziprasidone is combined with Meclofenamic acid.

Check this interaction

Acetylsalicylic acid

Unknown severity

DB00945

The risk or severity of hypertension can be increased when Ziprasidone is combined with Acetylsalicylic acid.

Check this interaction

Dopamine

Unknown severity

DB00988

The risk or severity of hypertension can be increased when Ziprasidone is combined with Dopamine.

Check this interaction

Oxaprozin

Unknown severity

DB00991

The risk or severity of hypertension can be increased when Ziprasidone is combined with Oxaprozin.

Check this interaction

Showing 50 of 2165 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Take With Food

Take with food.

Toxicity & overdose

The most common adverse reactions reported with ziprasidone include somnolence, respiratory tract infections, extrapyramidal symptoms, dizziness, akathisia, abnormal vision, asthenia, vomiting, headache and nausea.
[L7342]

How it works

Mechanism of action

The effects of ziprasidone are differentiated from other antispychotics based on its preference and affinity for certain receptors. Ziprasidone binds to serotonin-2A (5-HT2A) and dopamine D2 receptors in a similar fashion to other atypical antipsychotics; however, one key difference is that ziprasidone has a higher 5-HT2A/D2 receptor affinity ratio when compared to other antipsychotics such as olanzapine, quetiapine, risperidone, and aripiprazole.[A363] Ziprasidone offers enhanced modulation of mood, notable negative symptom relief, overall cognitive improvement and reduced motor dysfunction which is linked to it's potent interaction with 5-HT2C, 5-HT1D, and 5-HT1A receptors in brain tissue.[A363] Ziprasidone can bind moderately to norepinephrine and serotonin reuptake sites which may contribute to its antidepressant and anxiolytic activity.[A363] Patient's taking ziprasidone will likely experience a lower incidence of orthostatic hypotension, cognitive disturbance, sedation, weight gain, and disruption in prolactin levels since ziprasidone has a lower affinity for histamine H1, muscarinic M1, and alpha1-adrenoceptors.[A363]

Pharmacodynamics

Ziprasidone is classified as a "second generation" or "atypical" antipsychotic and is a dopamine and 5HT2A receptor antagonist with a unique receptor binding profile. As previously mentioned, ziprasidone has a very high 5-HT2A/D2 affinity ratio, binds to multiple serotonin receptors in addition to 5-HT2A, and blocks monoamine transporters which prevents 5HT and NE reuptake. On the other hand, ziprasidone has a low affinity for muscarinic cholinergic M1, histamine H1, and alpha1-adrenergic receptors.[A174562]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

In the absence of food, ziprasidone's oral bioavailability is 60%, and absorption may reach 100% if ziprasidone is taken with a meal containing at least 500 kcal. The difference in bioavailability has little to do with the fat content of the food and appears to be related to the bulk of the meal since more absorption occurs the longer ziprasidone remains in the stomach.
[A174562]

Half-life

The half life of ziprasidone is 6-7 hours.
[A174562]

Protein binding

Ziprasidone is extensively protein bound with over 99% of the drug bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
[A190594][L7342]

Volume of distribution

The mean apparent volume of distribution of Ziprasidone is 1.5 L/kg.
[L7342]

Metabolism

Ziprasidone is heavily metabolized in the liver with less than 5% of the drug excreted unchanged in the urine.
[A174277]
The primary reductive pathway is catalyzed by aldehyde oxidase, while 2 other less prominent oxidative pathways are catalyzed by CYP3A4.
[A174277]
Ziprasidone is unlikely to interact with other medications metabolized by CYP3A4 since only 1/3 of the antipsychotic is metabolized by the CYP3A4 system.
[A174277]

There are 12 identified ziprasidone metabolites (abbreviations italicized): Ziprasidone sulfoxide, ziprasidone sulfone, (6-chloro-2-oxo-2,3-dihydro-1H-indol-5-yl)acetic acid (OX-COOH), OX-COOH glucuronide, 3-(piperazine-1-yl)-1,2-benzisothiazole (BITP), BITP sulfoxide, BITP sulfone, BITP sulfone lactam, S-Methyl-dihydro-ziprasidone, S-Methyl-dihydro-ziprasidone-sulfoxide, 6-chloro-5-(2-piperazin-1-yl-ethyl)-1,3-dihydro-indol-2-one (OX-P), and dihydro-ziprasidone-sulfone.
[A190558]

As suggested by the quantity of metabolites, ziprasidone is metabolized through several different pathways. Ziprasidone is sequentially oxidized to ziprasidone sulfoxide and ziprasidone sulfone, and oxidative N-dealkylation of ziprasidone produces OX-COOH and BITP.
[A190558]
OX-COOH undergoes phase II metabolism to yield a glucuronidated metabolite while BITP is sequentially oxidized into BITP sulfoxide, BITP sulfone, then BITP sulfone lactam.
[A190558]
Ziprasidone can also undergo reductive cleavage and methylation to produce S-Methyl-dihydro-ziprasidone and then further oxidation to produce S-Methyl-dihydro-ziprasidone-sulfoxide.
[A190558]
Finally dearylation of ziprasidone produces OX-P, and the process of hydration and oxidation transforms the parent drug into dihydro-ziprasidone-sulfone.
[A190558]

Although CYP3A4 and aldehyde oxidase are the primary enzymes involved in ziprasidone metabolism[A174277], the pathways associated with each enzyme have not been specified.

Route of elimination

Ziprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug.

Clearance

The mean apparent systemic clearance is 7.5 mL/min/kg.
[L7342]

Drug targets(27)

Proteins and enzymes this drug interacts with in the body

D(2) dopamine receptor

BE0000756

DRD2

antagonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase .
PMID:21645528
Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

5-hydroxytryptamine receptor 2A

BE0000451

HTR2A

antagonist

Specific function1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:1330647 PMID:18703043 PMID:19057895 PMID:21645528 PMID:22300836 PMID:35084960 PMID:38552625

Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) .
PMID:28129538 PMID:35084960
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:28129538 PMID:35084960
HTR2A is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:28129538 PMID:35084960

Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:28129538 PMID:35084960
Affects neural activity, perception, cognition and mood .
PMID:18297054
Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction (By similarity)

5-hydroxytryptamine receptor 1A

BE0000291

HTR1A

agonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:37935376 PMID:37935377 PMID:8138923 PMID:8393041

Also functions as a receptor for various drugs and psychoactive substances .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:38552625 PMID:8138923 PMID:8393041

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:8138923 PMID:8393041

HTR1A is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission: signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores .
PMID:33762731 PMID:35610220
Beta-arrestin family members regulate signaling by mediating both receptor desensitization and resensitization processes .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the response to anxiogenic stimuli PMID:18476671 PMID:20363322 PMID:20945968

5-hydroxytryptamine receptor 1D

BE0000659

HTR1D

antagonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:10452531 PMID:1565658 PMID:1652050 PMID:33762731

Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances .
PMID:10452531 PMID:1565658 PMID:1652050 PMID:33762731

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:10452531 PMID:1565658 PMID:1652050 PMID:33762731

HTR1D is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission by inhibiting adenylate cyclase activity .
PMID:33762731
Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity .
PMID:18476671 PMID:20945968
May also play a role in regulating the release of other neurotransmitters .
PMID:18476671 PMID:20945968
May play a role in vasoconstriction PMID:18476671 PMID:20945968

5-hydroxytryptamine receptor 2C

BE0000533

HTR2C

antagonist

Specific function1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:12970106 PMID:18703043 PMID:19057895 PMID:29398112 PMID:7895773

Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) .
PMID:19057895 PMID:29398112
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:18703043 PMID:29398112
HTR2C is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:29398112
Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:29398112
Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelanocortin neurons and the release of CRH that then regulates the release of corticosterone (By similarity). Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress (By similarity). Plays a role in insulin sensitivity and glucose homeostasis (By similarity)

Metabolizing enzymes(2)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

AOX1Aldehyde oxidase

substrate

Transporters(1)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Carriers(2)

Proteins that carry this drug through the body

Albumin

BE0000530

ALB

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

Alpha-1-acid glycoprotein 1

BE0000925

ORM1

Cellular location

Secreted

General function & pharmacology

Functions as a transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body.

Appears to function in modulating the activity of the immune system during the acute-phase reaction

Scientific references(11)

Stahl S.M., Shayegan D.K.

Deconstructing Psychiatric Disorders, Part 1.

The Journal of Clinical Psychiatry

200364(9):982-983. doi: 10.4088/jcp.v64n0901

PMID: 14728084 DOI: 10.4088/jcp.v64n0901

Schmidt A.W., Lebel L.A., Howard HR Jr, Zorn S.H.

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.

European Journal of Pharmacology

2001425(3):197-201. doi: 10.1016/s0014-2999(01)01188-8

PMID: 11513838 DOI: 10.1016/s0014-2999(01)01188-8

Beedham C., Miceli J.J., Obach R.S.

Ziprasidone metabolism, aldehyde oxidase, and clinical implications.

Journal Clinical Psychopharmacology

2003 Jun23(3):229-32. doi: 10.1097/01.jcp.0000084028.22282.f2

PMID: 12826984 DOI: 10.1097/01.jcp.0000084028.22282.f2

Mattei C., Rapagnani M.P., Stahl S.M.

Ziprasidone hydrocloride: what role in the management of schizophrenia? J Cent Nerv Syst Dis. 2011 Feb 15;3:1-16. doi: 10.4137/JCNSD.

S4138

Print 2011

PMID: 23861634 DOI: 10.4137/JCNSD.S4138

Bouchette D., Marwaha R.

Mémoires de Robert-S.-M. Bouchette. Classiques des sciences sociales.. 2006. doi: 10.1522/cla.

boe

mem

PMID: 28846230 DOI: 10.1522/cla.boe.mem

Kutcher S., Brooks S.J., Gardner D.M., Honer B., Kopala L., Labelle A., Lalonde P., Malla A., Milliken H., Soni J., Williams R.

Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.

Neuropsychiatr Diseases Treat

2005 Jun1(2):89-108. doi: 10.2147/nedt.1.2.89.61042

PMID: 18568067 DOI: 10.2147/nedt.1.2.89.61042

Murray R., Correll C.U., Reynolds G.P., Taylor D.

Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria.

Therapeutics Advanced Psychopharmacology

2017 Mar7(1 Suppl):1-14. doi: 10.1177/2045125317693200. Epub 2017 Mar 1

PMID: 28344764 DOI: 10.1177/2045125317693200

Dayabandara M., Hanwella R., Ratnatunga S., Seneviratne S., Suraweera C., de Silva V.A.

Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.

Neuropsychiatr Diseases Treat

2017 Aug 2213:2231-2241. doi: 10.2147/NDT.S113099. eCollection 2017

PMID: 28883731 DOI: 10.2147/NDT.S113099

Wilner K.D., Demattos S.B., Anziano R.J., Apseloff G., Gerber N.

Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers.

British Journal of Clinical Pharmacology

200049(S1):43-47. doi: 10.1046/j.1365-2125.2000.00152.x

PMID: 10771453 DOI: 10.1046/j.1365-2125.2000.00152.x

Prakash C., Kamel A., Gummerus J., Wilner K.

A Personal Tribute.

Current Drug Metabolism

20067(8):1-2. doi: 10.2174/138920006779010557

PMID: 9224781 DOI: 10.2174/138920006779010557

Uzelac T.N., Nikolic-Kokic A.L., Spasic S.D., Macvanin M.T., Nikolic M.R., Mandic L.M., Jovanovic V.B.

Opposite clozapine and ziprasidone effects on the reactivity of plasma albumin SH-group are the consequence of their different binding properties dependent on protein fatty acids content.

Chemistry Biological Interact

2019 Sep 25311:108787. doi: 10.1016/j.cbi.2019.108787. Epub 2019 Aug 7

PMID: 31400341 DOI: 10.1016/j.cbi.2019.108787

ATC classification(1 code)

ATC N05AE04

Affected organisms(1)

Humans and other mammals

Salt forms(2)

Ziprasidone hydrochloride(DBSALT000810)

Ziprasidone mesylate trihydrate(DBSALT000811)

Experimental properties(2)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(1)

8wty

Commercial products(288)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Ziprasidone

DB00246

CAS number

146939-27-7

UNII (FDA)

6UKA5VEJ6X

InChI Key (molecular fingerprint)

MVWVFYHBGMAFLY-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

11753

ChEBI

10119

PubChem Compound

60854

PubChem Substance

46507627

KEGG Compound

C07568

KEGG Drug

D08687

ChemSpider

54841

BindingDB

50048803

PharmGKB

PA451974

PDB

XEF

Therapeutic Targets Database

DAP000079

IUPHAR

Guide to Pharmacology

Wikipedia

Ziprasidone

ChEMBL

CHEMBL708

ZINC

ZINC000000538550

RxCUI

115698

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5289

GenAtlas

HTR1D

GeneCards

HTR1D

GenBank Gene Database

M89955

GenBank Protein Database

177772

IUPHAR

Guide to Pharmacology

UniProtKB

P28221

UniProt Accession

5HT1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1960

GenAtlas

CHRNA7

GeneCards

CHRNA7

GenBank Gene Database

X70297

GenBank Protein Database

496607

IUPHAR

468

Guide to Pharmacology

468

UniProtKB

P36544

UniProt Accession

ACHA7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3026

GenAtlas

DRD5

GeneCards

DRD5

GenBank Gene Database

X58454

GenBank Protein Database

32049

IUPHAR

218

Guide to Pharmacology

218

UniProtKB

P21918

UniProt Accession

DRD5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3024

GenAtlas

DRD3

GeneCards

DRD3

GenBank Gene Database

U32499

GenBank Protein Database

927342

IUPHAR

216

Guide to Pharmacology

216

UniProtKB

P35462

UniProt Accession

DRD3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3025

GenAtlas

DRD4

GeneCards

DRD4

GenBank Gene Database

L12398

GenBank Protein Database

291946

IUPHAR

217

Guide to Pharmacology

217

UniProtKB

P21917

UniProt Accession

DRD4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5287

GenAtlas

HTR1B

GeneCards

HTR1B

GenBank Gene Database

D10995

GenBank Protein Database

219679

IUPHAR

Guide to Pharmacology

UniProtKB

P28222

UniProt Accession

5HT1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5291

GenAtlas

HTR1E

GeneCards

HTR1E

GenBank Gene Database

M91467

GenBank Protein Database

177774

IUPHAR

Guide to Pharmacology

UniProtKB

P28566

UniProt Accession

5HT1E_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5301

GenAtlas

HTR6

GeneCards

HTR6

GenBank Gene Database

L41147

GenBank Protein Database

1162924

IUPHAR

Guide to Pharmacology

UniProtKB

P50406

UniProt Accession

5HT6R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5302

GenAtlas

HTR7

GeneCards

HTR7

GenBank Gene Database

U68487

GenBank Protein Database

1857143

IUPHAR

Guide to Pharmacology

UniProtKB

P34969

UniProt Accession

5HT7R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5182

GenAtlas

HRH1

GeneCards

HRH1

GenBank Gene Database

Z34897

GenBank Protein Database

510296

IUPHAR

262

Guide to Pharmacology

262

UniProtKB

P35367

UniProt Accession

HRH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1950

GenAtlas

CHRM1

GeneCards

CHRM1

GenBank Gene Database

X52068

GenBank Protein Database

34451

IUPHAR

Guide to Pharmacology

UniProtKB

P11229

UniProt Accession

ACM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1951

GenAtlas

CHRM2

GeneCards

CHRM2

GenBank Gene Database

M16404

GenBank Protein Database

177990

IUPHAR

Guide to Pharmacology

UniProtKB

P08172

UniProt Accession

ACM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1952

GenAtlas

CHRM3

GeneCards

CHRM3

GenBank Gene Database

X15266

GenBank Protein Database

32324

IUPHAR

Guide to Pharmacology

UniProtKB

P20309

UniProt Accession

ACM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1953

GenAtlas

CHRM4

GeneCards

CHRM4

GenBank Gene Database

M16405

GenBank Protein Database

61970253

IUPHAR

Guide to Pharmacology

UniProtKB

P08173

UniProt Accession

ACM4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1954

GenAtlas

CHRM5

GeneCards

CHRM5

GenBank Gene Database

M80333

GenBank Protein Database

177988

IUPHAR

Guide to Pharmacology

UniProtKB

P08912

UniProt Accession

ACM5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5297

GenAtlas

HTR3A

GeneCards

HTR3A

GenBank Gene Database

D49394

GenBank Protein Database

681914

IUPHAR

373

Guide to Pharmacology

373

UniProtKB

P46098

UniProt Accession

5HT3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5298

GeneCards

HTR3B

Guide to Pharmacology

374

UniProtKB

O95264

UniProt Accession

5HT3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24003

GeneCards

HTR3C

UniProtKB

Q8WXA8

UniProt Accession

5HT3C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24004

GeneCards

HTR3D

UniProtKB

Q70Z44

UniProt Accession

5HT3D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24005

GeneCards

HTR3E

UniProtKB

A5X5Y0

UniProt Accession

5HT3E_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5300

GeneCards

HTR5A

Guide to Pharmacology

UniProtKB

P47898

UniProt Accession

5HT5A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:553

GeneCards

AOX1

GenBank Gene Database

L11005

GenBank Protein Database

438656

Guide to Pharmacology

3186

UniProtKB

Q06278

UniProt Accession

AOXA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8498

GenAtlas

ORM1

GeneCards

ORM1

GenBank Gene Database

X02544

GenBank Protein Database

757907

UniProtKB

P02763

UniProt Accession

A1AG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

International reference pricing

10 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $1.86/capsule

To $1407.72/syringe

Zeldox 20 mg Capsule

$1.86/capsule

Zeldox 40 mg Capsule

$2.13/capsule

Zeldox 60 mg Capsule

$2.13/capsule

Zeldox 80 mg Capsule

$2.13/capsule

Geodon 20 mg capsule

$8.14/capsule

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

All patents expired, 9 expired

7175855

United States

Approved 13 Feb 2007 · Expires 18 May 2020

Expired

6150366

United States

Approved 21 Nov 2000 · Expires 27 May 2019

Expired

6245766

United States

Approved 12 Jun 2001 · Expires 18 Dec 2018

Expired

2256227

Canada

Approved 1 Jul 2003 · Expires 16 Dec 2018

Expired

6232304

United States

Approved 15 May 2001 · Expires 1 Apr 2017

Expired

Patent protection has expired — generic versions may be available.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Ziprasidone 80mg capsules

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
32

Chemical identifiers

Ziprasidone

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Ziprasidone 80mg capsules

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science32

Chemical identifiers

Ziprasidone

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
32